Beijing Biote Pharmaceutical Co., Ltd
Beijing Biote Pharmaceutical Co., ltd was founded in 2004, certified as high-tech enterprise by Beijing Science and Technology Commission. The company holds China CFDA GMP certification, microsphere drug research and manufacture certification issued by Beijing Drug Administration. The company is specialized in microsphere drug research, manufacture and marketing. It is the first domestic company which is approved to make microsphere product for injection.
In 2009 Beijing Biote Pharma’s key product "leuprorelin acetate sterile lyophilized microspheres sustained release for injection" was granted by CFDA. It was the first generic marketed in China and awarded as Year 2009 Top 10 blockbuster new drug. The successful launch of this product terminated the monopoly of microsphere drugs by US, EU, Japanese companies in China. The dream of Chinese made microspheres for injection became reality on that day.
Being an integrated and highly motivated company committed to innovation, quality and marketing it achieved 33 million USD in 2015, 50 million USD in 2016, 60 million USD in 2017, 80 million USD in 2018, 98 million USD in 2019, 137 million USD in 2020. Our sale force and distributing agents covers 28 provinces, 129 cities and more than 800 hospitals, out of which 30% are covered by sale reps directly employed by the company.
Providing products and services of the HIGHEST QUALITY ON TIME
Fostering mutually beneficial relations with all our business partners
Managing our operations – to maintain the highest regulatory cGMP standards and full compliance with health, safety and environmental regulations
Being a responsible corporate citizen